Table of Content

1. Executive Summary
   1.1. Europe Biosimilars Market Snapshot, 2024 and 2031
   1.2. Market Opportunity Assessment, 2024 - 2031, US$ Mn
   1.3. Key Market Trends
   1.4. Future Market Projections
   1.5. Premium Market Insights
   1.6. Industry Developments and Key Market Events
   1.7. PMR Analysis and Recommendations
2. Market Overview
   2.1. Market Scope and Definition
   2.2. Market Dynamics
       2.2.1. Drivers
       2.2.2. Restraints
       2.2.3. Opportunity
       2.2.4. Key Trends
   2.3. Macro-Economic Factors
       2.3.1. Europe Sectorial Outlook
       2.3.2. Europe GDP Growth Outlook
   2.4. COVID-19 Impact Analysis
   2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
   3.1. Product Adoption Analysis
   3.2. Recent Product Approvals and Launches Insights
   3.3. Regulatory Landscape
   3.4. Value Chain Analysis
   3.5. PESTLE Analysis
   3.6. Porter’s Five Force Analysis
4. Europe Biosimilars Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   4.1. Key Highlights
       4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
       4.1.2. Absolute $ Opportunity
   4.2. Market Size (US$ Mn) Analysis and Forecast
       4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2022
       4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2023-2031
   4.3. Europe Biosimilars Market Outlook: Drug
       4.3.1. Introduction / Key Findings
       4.3.2. Historical Market Size (US$ Mn) Analysis, By Drug, 2019 - 2022
       4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Drug, 2023 - 2031
           4.3.3.1. Adalimumab
           4.3.3.2. Bevacizumab
           4.3.3.3. Trastuzumab
           4.3.3.4. Rituximab
           4.3.3.5. Infliximab
           4.3.3.6. Etanercept
           4.3.3.7. Epoetin alfa
           4.3.3.8. Filgrastim
           4.3.3.9. Other Biosimilars
       4.3.4. Market Attractiveness Analysis: Drug
   4.4. Europe Biosimilars Market Outlook: Drug Class
       4.4.1. Introduction / Key Findings
       4.4.2. Historical Market Size (US$ Mn) Analysis, By Drug Class, 2019 - 2022
       4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2023 - 2031
           4.4.3.1. Antirheumatics
           4.4.3.2. TNF Alfa Inhibitors
           4.4.3.3. VEGF/VEGFR Inhibitors
           4.4.3.4. HER2 Inhibitors
           4.4.3.5. Selective Immunosuppressant’s
           4.4.3.6. Interleukin Inhibitors
       4.4.4. Market Attractiveness Analysis: Drug Class
   4.5. Europe Biosimilars Market Outlook: Indication
       4.5.1. Introduction / Key Findings
       4.5.2. Historical Market Size (US$ Mn) Analysis, By Indication, 2019 - 2022
       4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
           4.5.3.1. Oncology Diseases
           4.5.3.2. Autoimmune Diseases
           4.5.3.3. Skin Disorders
           4.5.3.4. Inflammatory Bowel Disease (IBD)
           4.5.3.5. Rare Diseases
           4.5.3.6. Others
       4.5.4. Market Attractiveness Analysis: Indication
   4.6. Europe Biosimilars Market Outlook: Distribution Channel
       4.6.1. Introduction / Key Findings
       4.6.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2019 - 2022
       4.6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2023 - 2031
           4.6.3.1. Hospital Pharmacies
           4.6.3.2. Retail Pharmacies
           4.6.3.3. Online Pharmacies
       4.6.4. Market Attractiveness Analysis: Distribution Channel
5. Europe Biosimilars Market Outlook: Country
   5.1. Key Highlights
   5.2. Historical Market Size (US$ Mn) Analysis, By Country, 2019 - 2022
   5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031
       5.3.1. Germany
       5.3.2. France
       5.3.3. U.K.
       5.3.4. Italy
       5.3.5. Spain
       5.3.6. Russia
       5.3.7. Rest of Europe
   5.4. Market Attractiveness Analysis: Country
6. Germany Biosimilars Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   6.1. Key Highlights
   6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2022
       6.2.1. By Drug
       6.2.2. By Drug Class
       6.2.3. By Indication
       6.2.4. By Distribution Channel
   6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Drug, 2023 - 2031
       6.3.1. Adalimumab
       6.3.2. Bevacizumab
       6.3.3. Trastuzumab
       6.3.4. Rituximab
       6.3.5. Infliximab
       6.3.6. Etanercept
       6.3.7. Epoetin alfa
       6.3.8. Filgrastim
       6.3.9. Other Biosimilars
   6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2023 - 2031
       6.4.1. Antirheumatics
       6.4.2. TNF Alfa Inhibitors
       6.4.3. VEGF/VEGFR Inhibitors
       6.4.4. HER2 Inhibitors
       6.4.5. Selective Immunosuppressant’s
       6.4.6. Interleukin Inhibitors
   6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
       6.5.1. Oncology Diseases
       6.5.2. Autoimmune Diseases
       6.5.3. Skin Disorders
       6.5.4. Inflammatory Bowel Disease (IBD)
       6.5.5. Rare Diseases
       6.5.6. Others
   6.6. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2023 - 2031
       6.6.1. Hospital Pharmacies
       6.6.2. Retail Pharmacies
       6.6.3. Online Pharmacies
   6.7. Market Attractiveness Analysis
7. France Biosimilars Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   7.1. Key Highlights
   7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2022
       7.2.1. By Drug
       7.2.2. By Drug Class
       7.2.3. By Indication
       7.2.4. By Distribution Channel
   7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Drug, 2023 - 2031
       7.3.1. Adalimumab
       7.3.2. Bevacizumab
       7.3.3. Trastuzumab
       7.3.4. Rituximab
       7.3.5. Infliximab
       7.3.6. Etanercept
       7.3.7. Epoetin alfa
       7.3.8. Filgrastim
       7.3.9. Other Biosimilars
   7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2023 - 2031
       7.4.1. Antirheumatics
       7.4.2. TNF Alfa Inhibitors
       7.4.3. VEGF/VEGFR Inhibitors
       7.4.4. HER2 Inhibitors
       7.4.5. Selective Immunosuppressant’s
       7.4.6. Interleukin Inhibitors
   7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
       7.5.1. Oncology Diseases
       7.5.2. Autoimmune Diseases
       7.5.3. Skin Disorders
       7.5.4. Inflammatory Bowel Disease (IBD)
       7.5.5. Rare Diseases
       7.5.6. Others
   7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2023 - 2031
       7.6.1. Hospital Pharmacies
       7.6.2. Retail Pharmacies
       7.6.3. Online Pharmacies
   7.7. Market Attractiveness Analysis
8. UK Biosimilars Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
8.1. Key Highlights
   8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2022
       8.2.1. By Drug
       8.2.2. By Drug Class
       8.2.3. By Indication
       8.2.4. By Distribution Channel
   8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Drug, 2023 - 2031
       8.3.1. Adalimumab
       8.3.2. Bevacizumab
       8.3.3. Trastuzumab
       8.3.4. Rituximab
       8.3.5. Infliximab
       8.3.6. Etanercept
       8.3.7. Epoetin alfa
       8.3.8. Filgrastim
       8.3.9. Other Biosimilars
   8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2023 - 2031
       8.4.1. Antirheumatics
       8.4.2. TNF Alfa Inhibitors
       8.4.3. VEGF/VEGFR Inhibitors
       8.4.4. HER2 Inhibitors
       8.4.5. Selective Immunosuppressant’s
       8.4.6. Interleukin Inhibitors
   8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
       8.5.1. Oncology Diseases
       8.5.2. Autoimmune Diseases
       8.5.3. Skin Disorders
       8.5.4. Inflammatory Bowel Disease (IBD)
       8.5.5. Rare Diseases
       8.5.6. Others
   8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2023 - 2031
       8.6.1. Hospital Pharmacies
       8.6.2. Retail Pharmacies
       8.6.3. Online Pharmacies
   8.7. Market Attractiveness Analysis
9. Italy Biosimilars Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   9.1. Key Highlights
   9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2022
       9.2.1. By Drug
       9.2.2. By Drug Class
       9.2.3. By Indication
       9.2.4. By Distribution Channel
   9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Drug, 2023 - 2031
       9.3.1. Adalimumab
       9.3.2. Bevacizumab
       9.3.3. Trastuzumab
       9.3.4. Rituximab
       9.3.5. Infliximab
       9.3.6. Etanercept
       9.3.7. Epoetin alfa
       9.3.8. Filgrastim
       9.3.9. Other Biosimilars
   9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2023 - 2031
       9.4.1. Antirheumatics
       9.4.2. TNF Alfa Inhibitors
       9.4.3. VEGF/VEGFR Inhibitors
       9.4.4. HER2 Inhibitors
       9.4.5. Selective Immunosuppressant’s
       9.4.6. Interleukin Inhibitors
   9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
       9.5.1. Oncology Diseases
       9.5.2. Autoimmune Diseases
       9.5.3. Skin Disorders
       9.5.4. Inflammatory Bowel Disease (IBD)
       9.5.5. Rare Diseases
       9.5.6. Others
   9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2023 - 2031
       9.6.1. Hospital Pharmacies
       9.6.2. Retail Pharmacies
       9.6.3. Online Pharmacies
   9.7. Market Attractiveness Analysis
10. Spain Biosimilars Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   10.1. Key Highlights
   10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2022
       10.2.1. By Drug
       10.2.2. By Drug Class
       10.2.3. By Indication
       10.2.4. By Distribution Channel
   10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Drug, 2023 - 2031
       10.3.1. Adalimumab
       10.3.2. Bevacizumab
       10.3.3. Trastuzumab
       10.3.4. Rituximab
       10.3.5. Infliximab
       10.3.6. Etanercept
       10.3.7. Epoetin alfa
       10.3.8. Filgrastim
       10.3.9. Other Biosimilars
   10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2023 - 2031
       10.4.1. Antirheumatics
       10.4.2. TNF Alfa Inhibitors
       10.4.3. VEGF/VEGFR Inhibitors
       10.4.4. HER2 Inhibitors
       10.4.5. Selective Immunosuppressant’s
       10.4.6. Interleukin Inhibitors
   10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
       10.5.1. Oncology Diseases
       10.5.2. Autoimmune Diseases
       10.5.3. Skin Disorders
       10.5.4. Inflammatory Bowel Disease (IBD)
       10.5.5. Rare Diseases
       10.5.6. Others
   10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2023 - 2031
       10.6.1. Hospital Pharmacies
       10.6.2. Retail Pharmacies
       10.6.3. Online Pharmacies
   10.7. Market Attractiveness Analysis
11. Russia Biosimilars Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   11.1. Key Highlights
   11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2022
       11.2.1. By Drug
       11.2.2. By Drug Class
       11.2.3. By Indication
       11.2.4. By Distribution Channel
   11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Drug, 2023 - 2031
       11.3.1. Adalimumab
       11.3.2. Bevacizumab
       11.3.3. Trastuzumab
       11.3.4. Rituximab
       11.3.5. Infliximab
       11.3.6. Etanercept
       11.3.7. Epoetin alfa
       11.3.8. Filgrastim
       11.3.9. Other Biosimilars
   11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2023 - 2031
       11.4.1. Antirheumatics
       11.4.2. TNF Alfa Inhibitors
       11.4.3. VEGF/VEGFR Inhibitors
       11.4.4. HER2 Inhibitors
       11.4.5. Selective Immunosuppressant’s
       11.4.6. Interleukin Inhibitors
   11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
       11.5.1. Oncology Diseases
       11.5.2. Autoimmune Diseases
       11.5.3. Skin Disorders
       11.5.4. Inflammatory Bowel Disease (IBD)
       11.5.5. Rare Diseases
       11.5.6. Others
   11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2023 - 2031
       11.6.1. Hospital Pharmacies
       11.6.2. Retail Pharmacies
       11.6.3. Online Pharmacies
   11.7. Market Attractiveness Analysis
12. Competition Landscape
   12.1. Market Share Analysis, 2023
   12.2. Market Structure
       12.2.1. Competition Intensity Mapping By Market
       12.2.2. Competition Dashboard
   12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
       12.3.1. Siemens Healthineers
           12.3.1.1. Overview
           12.3.1.2. Segments and Product
           12.3.1.3. Key Financials
           12.3.1.4. Market Developments
           12.3.1.5. Market Strategy
       12.3.2. Biogen Inc.
       12.3.3. Celltrion, Inc.
       12.3.4. Pfizer Inc.
       12.3.5. Amgen Inc.
       12.3.6. Samsung Bioepis Co., Ltd.
       12.3.7. Biocon
       12.3.8. Viatris (Mylan Pharmaceuticals Inc.)
       12.3.9. Coherus BioSciences, Inc.
       12.3.10. Boehringer Ingelheim Pharmaceuticals, Inc.
       12.3.11. Eli Lilly and Company
       12.3.12. Bio-Thera Solutions, Ltd.
13. Appendix
   13.1. Research Methodology
   13.2. Research Assumptions
   13.3. Acronyms and Abbreviations